期刊文献+

综合治疗内分泌失调性骨质疏松症的疗效研究

Therapeutic Effect of Comprehensive Therapy on Endocrine Disorder Osteoporosis
下载PDF
导出
摘要 目的探讨综合疗法治疗内分泌失调性骨质疏松症的临床疗效。方法便利选择该院2016年6月—2017年9月收治的内分泌失调性骨质疏松症患者132例,以便利抽样法分为参照组和治疗组各66例,参照组采取常规疗法,治疗组采取综合治疗,对比两组患者临床疗效。结果治疗组总有效率98.48%高于参照组87.88%,NRS疼痛评分(2.72±1.38)分、骨折发生率1.52%低于参照组[NRS疼痛评分(5.24±1.66)分、骨折发生率10.61%],且股骨颈(817.25±59.75)mg/cm^3、Wards三角区(649.01±52.33)mg/cm^3、大转子(733.45±59.55)mg/cm^3骨密度值均高于参照组[股骨颈(784.26±43.84)mg/cm^3、Wards三角区(594.09±49.91)mg/cm^3、大转子(701.45±49.65)mg/cm^3](P<0.05)。结论综合疗法治疗内分泌失调性骨质疏松症可有效改善患者骨密度,降低骨折风险,值得临床应用。 Objective To investigate the clinical efficacy of comprehensive therapy in the treatment of endocrine dysregulated osteoporosis.Methods A total of 132 patients with endocrine dysregulated osteoporosis admitted to our hospital from June 2016 to September 2017 were convenient selected and enrolled.The patients were divided into a reference group and a treatment group by 66 cases.The reference group took conventional therapy and the treatment group took Comprehensive treatment,comparing the clinical efficacy of the two groups of patients.Results The total effective rate of the treatment group was 98.48%higher than that of the reference group(87.88%),the NRS pain score(2.72±1.38)points,and the fracture incidence rate was 1.52%lower than the reference group[NRS pain score(5.24±1.66)points,fracture incidence rate10.61%].The femoral neck(817.25±59.75)mg/cm^3,Wards triangle(649.01±52.33)mg/cm^3,and greater trochanter(733.45±59.55)mg/cm^3 bone mineral density were higher than the reference group[femoral neck(784.26±43.84)mg/cm^3,Wards triangle(594.09±49.91)mg/cm^3,greater trochanter(701.45±49.65)mg/cm3](P<0.05).Conclusion Comprehensive therapy for endocrine disorders of osteoporosis can effectively improve bone mineral density and reduce fracture risk,which is worthy of clinical application.
作者 胡显洁 孙燕 侯存 HU Xian-jie;SUN Yan;HOU Cun(Department of Endocrinology,Jining First People's Hospital,Jining,Shandong Province,272000 China;Department of Nephrology,Jining First People's Hospital,Jining,Shandong Province,272000 China)
出处 《中外医疗》 2019年第13期79-81,共3页 China & Foreign Medical Treatment
关键词 综合治疗 内分泌失调性骨质疏松 疗效观察 Comprehensive treatment Endocrine disorder osteoporosis Therapeutic effect observation
  • 相关文献

参考文献8

二级参考文献54

  • 1张智海,沈建雄,刘忠厚.中国人骨质疏松症诊断标准回顾性研究[J].中国骨质疏松杂志,2004,10(3):255-262. 被引量:111
  • 2张智海,刘忠厚.周围型双能X线骨密度仪(pDEXA)诊断技术[J].中国骨质疏松杂志,2006,12(4):409-414. 被引量:17
  • 3丁旭峰,刘萍.对中医药临床疗效评价体系建立的多方位思索[J].辽宁中医杂志,2007,34(5):577-579. 被引量:23
  • 4黄院英,杨玉生,洪侃,石维.内分泌失调性骨质疏松症综合治疗的临床体会[J].实用医技杂志,2007,14(27):3703-3705. 被引量:11
  • 5Rossini, M. Acute phase response after zoledronic acid is associated with long-term effects on white blood cells. Calcif Tissue International, 2013, 93 ( 3 ) :249-252.
  • 6Silverman SL, Kriegman A, Goncalves J, et al. Effect of acetaminophen and fluvastatin on post-dose symptoms following infusion of zoledronic acid. Osteoporosis International, 2011, 22 (8) : 2337-2345.
  • 7Wark J, Recknor C, Ryabitseva O, et al. Treatment with acetaminophen/paracetamol or ibuprofen alleviates post-dose symptoms related to intravenous infusion with zoledronic acid 5 mg. Osteoporosis International, 2012,23 ( 2 ) : 503-512.
  • 8Lewiecki EM. Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect. Core Evid, 2009, 4(1) :13-23.
  • 9Dicuonzo G, Vincenzi B, Santini D, et al. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6. J Interferon Cytokine Res, 2003,23 (11 ) : 649-654.
  • 10Reid I R. Characterization of and risk factors for the acute-phase response after zoledronic acid. J Clin Endocrinol Metab, 2010, 95(9). 4380-4387.

共引文献1177

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部